Streetbeat News

Analyst Ratings

CMCSA

Rosenblatt analyst Barton Crockett has maintained a Neutral rating on Comcast Corporation (NASDAQ:CMCSA) and increased the price target from $44 to $46. This adjustment reflects a modestly more positive outlook on the company's stock value.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 5:13 pm

CHTR

Rosenblatt analyst Barton Crockett maintains a Buy rating on Charter Communications (NASDAQ:CHTR) but reduces the price target from $482 to $475.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 5:09 pm

COIN

Coinbase Global, Inc. (NASDAQ:COIN) stock is up after JMP Securities and Mizuho analysts raised their price targets. JMP's Devin Ryan set a new target of $200, citing the potential of blockchain technology and digital asset ecosystem growth. Mizuho's Dan Dolev increased his target to $54, noting excitement over possible spot Bitcoin ETFs. COIN shares have surged over 60% in the past month and are up 400% YTD, reaching a new 52-week high of $178.05.

Portfolio Pulse from Erica Kollmann

December 22, 2023 | 5:08 pm

ALNY

AZN

IONS

The FDA approved AstraZeneca and Ionis Pharmaceuticals' Wainua for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. William Blair projects over $700 million in peak sales for Wainua and maintains an Outperform rating for Ionis, considering it a top pick for 2024. The analyst expects Wainua's price to match Alnylam's Amvuttra at around $463,500 per year, with a net price projection of $291,000. The ATTR-PN market is seen as large enough for multiple competitors, with potential indication expansion being a key commercial opportunity. Ionis shares rose 5.30% to $51.72.

Portfolio Pulse from Vandana Singh

December 22, 2023 | 5:04 pm

AON

BMO Capital has maintained its Market Perform rating for Aon (NYSE:AON) but lowered its price target from $350.00 to $325.00. Aon's shares are currently trading at $289.65, and the new price target suggests a potential upside of 12.2%. Aon is a global leader in insurance and reinsurance brokerage, as well as human resource solutions, with approximately 50,000 employees in over 120 countries.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 5:00 pm

BPMC

Raymond James has reaffirmed its Strong Buy rating on Blueprint Medicines (NASDAQ:BPMC) and increased its price target from $85.00 to $100.00. Blueprint Medicines' shares are currently trading at $85.93, and the new price target suggests a potential upside of 16.37%. Blueprint Medicines is a biopharmaceutical company focused on developing drugs for diseases caused by abnormal kinase activation.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 5:00 pm

TMCI

Six analysts have recently reviewed Treace Medical Concepts (NASDAQ:TMCI), with mixed opinions. The average 12-month price target is now $17.5, down from $21.75, with a high estimate of $28.00 and a low of $11.00. Analysts from firms like Truist Securities, Morgan Stanley, Stifel, and UBS have adjusted their ratings and price targets. Treace Medical Concepts is a commercial-stage orthopaedic medical device company with a patented procedure for bunion correction. The company has shown a revenue growth rate of 23.3% as of September 30, 2023, but has a net margin of -42.99% and an ROE of -12.17%. Its debt-to-equity ratio is 0.51, below the industry average.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 5:00 pm

AVO

Stephens & Co. has maintained its Overweight rating on Mission Produce (NASDAQ:AVO) but reduced its price target from $13.00 to $12.00. Mission Produce's shares have fallen 5.43% to $9.05. The new target implies a 32.6% upside. Mission Produce operates in avocado production and distribution, with additional services like ripening and logistical management. The company earns most revenue from its Marketing and Distribution segment.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 5:00 pm

BBWI

Wells Fargo has maintained its Equal-Weight rating on Bath & Body Works (NYSE:BBWI) and increased its price target from $35.00 to $40.00. Despite this, BBWI shares are currently trading down at $43.40, which is above the new target price. Bath & Body Works operates primarily in North America with a focus on home fragrance and body care retail, expecting growth through store reformatting and digital expansion.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 5:00 pm

AIR

Stifel has reaffirmed its Buy rating on AAR Corp (NYSE:AIR) and increased its price target from $80.00 to $81.00. Despite the upgrade, AAR's stock is currently down 5.35% at $67.00 per share. An increase to the new price target would represent a 20.9% upside. AAR provides products and services to the aviation, government, and defense sectors, with the majority of its revenue coming from the Aviation Services segment.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 5:00 pm